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DOI 10.1016/j.ccr.2012.02.018SUMMARYWe characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous leukemia (CML) using
a transgenic mouse model. LSC were restricted to cells with long-term hematopoietic stem cell (LTHSC)
phenotype. CML LTHSC demonstrated reduced homing and retention in the bone marrow (BM), related to
decreased CXCL12 expression in CML BM, resulting from increased G-CSF production by leukemia cells.
Altered cytokine expression in CML BM was associated with selective impairment of normal LTHSC growth
and a growth advantage to CML LTHSC. Imatinib (IM) treatment partially corrected abnormalities in cytokine
levels and LTHSC growth. These results were validated using human CML samples and provide improved
understanding of microenvironmental regulation of normal and leukemic LTHSC and their response to IM
in CML.INTRODUCTION
Chronic myelogenous leukemia (CML) is a lethal hematological
malignancy resulting from the transformation of a primitive
hematopoietic cell by the BCR-ABL oncogene (Sawyers,
1999). CML leukemia stem cells (LSCs) retain the ability to regen-
erate multilineage hematopoiesis (Fialkow et al., 1977) and
generate a vast expansion of malignant myeloid cells, which
retain differentiating capacity and displace residual normal
hematopoiesis. CML cells also demonstrate altered trafficking
resulting in increased numbers of circulating progenitors, extra-
medullary hematopoiesis, and massive splenomegaly (Petzer
et al., 1996). Leukemic cells acquire additional genetic abnor-
malities over time, leading to disease progression from an initial
chronic phase (CP) to advanced accelerated phase (AP) and
blast crisis (BC; Perrotti et al., 2010).Significance
Chronic myelogenous leukemia (CML) results from stem cell tr
kinase inhibitors (TKI) induce remission in CML patients but d
erate leukemia on drug discontinuation. Improved understa
pathogenesis and developing curative therapies. We show h
results in reduced retention of LSC in CML bone marrow (BM
expression in CML BM result in selective suppression of nor
changes were partially corrected by TKI treatment. These re
and could guide strategies for targeting this resistant populatBCR-ABL tyrosine kinase inhibitors (TKI) are effective in
inducing remission and prolonging survival in CP CML patients
(Druker et al., 2006; Kantarjian et al., 2010; Saglio et al., 2010).
However, TKI are less effective in targeting CML stem cells
compared to more mature leukemia cells (Corbin et al., 2011;
Graham et al., 2002; Holtz et al., 2002). As a result, LSC persist
despite TKI treatment (Chomel et al., 2011), and there is a high
frequency of leukemia relapse upon discontinuation of treat-
ment. Although a small subset of patients can discontinue TKI
treatment without disease recurrence, most patients need to
take TKIs indefinitely to prevent relapse (Mahon et al., 2010;
Michor et al., 2005), with associated risk of noncompliance,
toxicity, and considerable expense (Cortes et al., 2011).
Improved characterization of LSC is critical to a better under-
standing of CML pathogenesis and development of effective
therapeutic strategies.ansformation by the BCR-ABL oncogene. BCR-ABL tyrosine
o not eliminate leukemia stem cells (LSC), which can regen-
nding of LSC regulation is critical to understanding CML
ere that leukemia-induced decrease in CXCL12 expression
). Furthermore, leukemia-induced abnormalities in cytokine
mal stem cell growth and enhanced growth of LSC. These
sults improve our understanding of LSC regulation in CML
ion.
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Microenvironmental Regulation of CML Stem CellsIn vitro analysis of progenitor cells from CML patients has
revealed enhanced proliferation, reduced apoptosis, and
increased differentiation in culture compared to normal progen-
itors. However, in vivo characterization of LSC from CP CML
patients in immunodeficient mouse hosts is limited by low levels
of engraftment and lack of leukemia development. Expression of
BCR-ABL in murine cells using retroviral vectors followed by
transplantation into irradiated hosts results in development of
a myeloproliferative disorder (Li et al., 1999; Pear et al., 1998).
This model has been useful in studying molecular mechanisms
contributing to leukemia development. However, leukemia in
this model is quite fulminant, associated with pulmonary hemor-
rhage and death within four weeks, and may be more represen-
tative of advanced phase CML. In addition, although LSC are
known to be present within Lin-Sca-1+c-Kit+ (LSK) cells in this
model, they have not been characterized with a higher degree
of resolution.
An inducible transgenic mouse model of CML in which the
BCR-ABL gene is expressed under control of a Tet-regulated
30 enhancer of the murine stem cell leukemia (SCL) gene allows
targeted BCR-ABL expression in stem and progenitor cells
(Koschmieder et al., 2005; Schemionek et al., 2010). Induction
of BCR-ABL expression by tetracycline withdrawal results in
a chronic myeloproliferative disorder with neutrophilic leukocy-
tosis and splenomegaly that resembles CP CML. Leukemia is
reversed on re-introduction of tetracycline. This model allows
for the study of leukemogenesis in vivo under steady-state
conditions. In the current study, we used the transgenic BCR-
ABL model to study leukemia-induced alterations in the BM
microenvironment and their contributions to normal and CML
LTHSC cell growth and localization and to determine the effect
of TKI treatment on these alterations.
RESULTS
Development ofCPCML-likeMyeloproliferativeDisease
in BCR-ABL Mice
Induction of BCR-ABL expression in SCL-tTA/BCR-ABL trans-
genic mice (FVB/N background) by tetracycline withdrawal
resulted in 4 to 6 weeks in development of a CML-like myelopro-
liferative disorder characterized by neutrophilic leukocytosis
(Figure 1A), splenomegaly (Figure 1B), BM hypercellularity
(Figure 1C), and spleen infiltration with myeloid cells (Figure 1D).
A subset of mice developed BM fibrosis after eight or more
weeks (Figure 1E). Approximately 20%of mice developed lymph
node enlargement, with infiltration of lymph nodes, BM and
spleen with pro-B lymphoblastic cells (B220+CD43+CD19+IgM;
Figure 1F). The median survival after induction of BCR-ABL
expression was 56 days (Figure 1G). These observations
suggest that the BCR-ABL mouse model is representative of
CP CML and develops features of advanced phase CML with
prolonged BCR-ABL expression.
Changes in Stem and Progenitor Cell Populations in
BCR-ABL Mice
Changes in distribution of stem and progenitor populations in
the BM and spleen were observed within two weeks after induc-
tion of BCR-ABL expression and were more prominent after
eight weeks. Primitive LSK cells and granulocyte-macrophage578 Cancer Cell 21, 577–592, April 17, 2012 ª2012 Elsevier Inc.progenitors (GMP) were increased in the BM of BCR-ABL mice
compared to controls, whereas megakaryocyte-erythrocyte
progenitors (MEP) and common myeloid progenitors (CMP)
were decreased (Figures S1A–S1C). In normal hematopoiesis,
LTHSC capacity is restricted to the Flt3CD150+CD48LSK
subpopulation, whereas Flt3CD150CD48, Flt3CD150+
CD48+, and Flt3CD150CD48+ LSK cells represent multipotent
progenitors (MPP) lacking extensive self-renewal and long-term
engrafting capacity (Figure 2A; Akala et al., 2008; Kiel et al.,
2005). Although total LSK cell numbers were increased, LTHSC
numbers were markedly reduced in the BM of BCR-ABL mice
(Figures 2B and 2C). CD150CD48 MPP were also reduced in
the BM of BCR-ABL mice. Increased LSK cells represented
mainly Flt3CD48+ MPP and Flt3+ LSK cells representing
lymphoid-primed MPP (LMPP; Ma˚nsson et al., 2007). IL-
7Ra-expressing common lymphoid progenitors (CLP; Kondo
et al., 1997) were reduced in BCR-ABLmice. In summary, reduc-
tion in LTHSC is associated with an increase in CD48+ MPP,
LMPP, and GMP in the BM of BCR-ABL mice. BCR-ABL mice
demonstrated increased LTHSC numbers in the spleen
compared with controls (Figures 2D and 2E), together with
a vast increase in MPP, LMPP, CMP, and GMP, consistent
with increased extramedullary hematopoiesis (Figures 2D and
2E; Figures S1D and S1E available online). Reduced BM and
increased splenic LTHSC in BCR-ABL mice suggest altered
LTHSC trafficking and/or niche requirements.
Long-Term Engrafting and Leukemia-Initiating Capacity
Is Restricted to BCR-ABL+ LTHSC
SCL-tTA/BCR-ABL mice were crossed with transgenic GFP-
expressing mice to facilitate detection of donor cells after trans-
plantation. BCR-ABL expression was induced for four weeks
and GFP+ BM cells selected by flow cytometry and transplanted
into irradiated congenic recipient mice. We observed robust
engraftment of GFP+ donor cells and development of myelopro-
liferative disease in recipientmice (Figure S2A). Leukemia usually
developed within eight weeks posttransplant. Leukemia devel-
oping in recipient mice had a similar phenotype to that in donor
mice and was transplantable to secondary (Figure S2B) and
tertiary recipients (not shown). To identify subpopulations of
cells capable of long-term engraftment and leukemia-initiation,
GFP+ GMP, CMP, and LSK cells from BM of leukemic mice
were transplanted into irradiated congenic recipients. Trans-
plantation of LSK cells, but not CMP and GMP, resulted in
long-term engraftment and leukemia development in recipient
mice (Figure S2C). LSK cells from the spleen also engrafted
and generated leukemia in recipient mice (Figure S2D). The
frequency of functional long-term engrafting cells within the
BM LSK population measured using limiting dilution analysis
was significantly reduced in BCR-ABL compared to control
mice (Figure S2E), consistent with reduced numbers of cells
with LTHSC phenotype. Cells with the LTHSC phenotype gener-
ated robust long-term engraftment with predominantly myeloid
cells and development of CML-like myeloproliferative disease
(Figure 3A). In contrast, CD48+ MPP generated short-term
engraftment with predominantly myeloid cells for up to eight
weeks but did not sustain long-term engraftment. Sufficient
numbers of CD150CD48 MPP were not obtained from CML
mice for transplantation experiments. Transplantation of Flt3+
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Figure 1. Development of CML-like Myeloproliferative Disorder in SCL-tTA/BCR-ABL Transgenic Mice
(A–D) Development of amyeloproliferative disorder in SCL-tTA/BCR-ABL transgenicmicewithin 4–6weeks after induction of BCR-ABL expression bywithdrawal
of tetracycline, characterized by (A) neutrophilic leukocytosis and (B) splenomegaly (n = 20). Histopathological evaluation of (C) BM and (D) spleen tissue obtained
four weeks after induction of BCR-ABL expression showing leukocytic infiltration.
(E) Development of BM fibrosis ten weeks after induction of BCR-ABL expression as seen with hematoxylin and eosin (left), Trichrome (center), and reticulin (right)
staining.
(F) Development of pro-B lymphoblastic leukemia/lymphoma with lymph node enlargement (upper left panel), lymphoblastic infiltration of lymph nodes (upper
right panel), and expression of pro-B cell markers on flow cytometry (lower panel).
(G) Survival curve of SCL-tTA/BCR-ABL mice after BCR-ABL induction (n = 33). All scale bars represent a size of 100 mm.
Cancer Cell
Microenvironmental Regulation of CML Stem CellsLMPP frequently resulted in the development of lymphoid
tumors (not shown). Tumor cells did not engraft after transplan-
tation into secondary recipient mice. In mice that did not develop
tumors, Flt3+LMPP generated short-term engraftment of
lymphoblastic and myeloid cells, which was lost after 12 weeks.
These observations suggest a hierarchical organization of
leukemic LTHSC, MPP, and LMPP within LSK cells in BCR-
ABL mice, as with normal hematopoiesis, with self-renewaland long-term engraftment capacity restricted to LTHSC, which
was lost after differentiation to MPP. Despite having both
myeloid and lymphoid capacity, leukemic LTHSC generated
predominantly myeloid lineage cells. Interestingly, transplanta-
tion of limiting numbers of CML LTHSC often resulted in long-
term engraftment with BCR-ABL+ cells without development of
leukemia (Figures 3B and 3C). One in six BM cells with LTHSC
phenotype possessed long-term repopulation activity, whereasCancer Cell 21, 577–592, April 17, 2012 ª2012 Elsevier Inc. 579
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Figure 2. Changes in Stem and Progenitor Cell Populations in BCR-ABL-Expressing Mice
(A) The populations analyzed are shown and included LinSca-1+c-Kit+ (LSK) cells, which were further subdivided into Flt3CD150+CD48 (LTHSC);
Flt3CD150CD48, Flt3CD150+CD48+, and Flt3CD150CD48+ (MPP); and Flt3+CD150 cells (LMPP).
(B) Representative flow cytometry plots of LTHSC, MPP, and LMPP populations in the BM of control and BCR-ABL-expressing mice.
(C) Total numbers of LTHSC, CD150CD48, CD150+CD48, CD150CD48+ MPP, LMPP, and CLP (common lymphoid progenitor, LinSca-1Low
c-KitLowFlt3HighIL-7RaHigh) in the BM (per femur) of control and SCL-tTA/BCR-ABL mice at two and eight weeks after BCR-ABL induction (n = 6–8).
(D) Representative flow cytometry plots of LTHSC, MPP, and LMPP in the spleen of control mice and BCR-ABL-expressing mice.
(E) Total numbers of LTHSC, CD150CD48-, CD150+CD48, CD150CD48+ MPP, LMPP, and CLP in the spleen of control mice and SCL-tTA/BCR-ABL mice at
two and eight weeks after BCR-ABL induction. Results represent mean ± SEM. Significance values: *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant, n = 6–8.
See also Figure S1.
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Figure 3. Long-Term Engraftment and Leukemia Induction by BCR-ABL-Expressing LTHSC
(A) Levels of donor GFP+ cells in peripheral blood after transplantation of BCR-ABL-expressing LTHSC (500 cells/mouse), MPP1 (CD150+CD48;2,000 cells/
mouse), andMPP2 (CD150CD48+; 2,000 cells/mouse) into irradiated recipients. Mice were followed for 16 weeks. Themean ± SEM is shown. (B) Engraftment of
GFP+ cells in peripheral blood and (C) peripheral blood WBC counts in recipient mice after transplantation of BCR-ABL-expressing LTHSC in limiting dilutions.
Red spots indicate mice that died of leukemia within 20 weeks. The calculated frequency of functional long-term engrafting and leukemia-initiating cells within
cells with LTHSC (LinSca-1+Kit+Flt3-CD150+CD48) phenotype in the (D) BM and (E) spleen of BCR-ABLmice is shown. The 95%confidence interval for LTHSC
and LSC in the BM is 1/15-1/2 and 1/198-1/34, respectively. The 95% confidence interval for LTHSC and LSC in the spleen is 1/21-1/4 and 1/286-1/62,
respectively.
See also Figure S2.
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Microenvironmental Regulation of CML Stem Cells1 in 80 BMLTHSCwere capable of initiating leukemia (defined as
development of leukocytosis) within 20 weeks (Figure 3D), sug-
gesting heterogeneity in leukemia-initiating capacity of individual
BCR-ABL+ LTHSC. The frequency of functional, long-term en-
grafting stem cells and leukemia-inducing cells within phenotyp-
ically defined LTHSC in the spleen was similar to BM LTHSC
(Figure 3E).BCR-ABL Expression and Cell Cycle Status of LTHSC
Expression of BCR-ABL mRNA levels was higher in LSK cells
compared with CMP, GMP, and MEP cells (Figure S3A). Within
LSK cells, BCR-ABL expression was higher in MPP compared
with LTHSC but was reduced in LMPP (Figure S3B). Although
the BCR-ABL transgene expression through the SCL promoter
in transgenic mice may differ from expression driven by theCancer Cell 21, 577–592, April 17, 2012 ª2012 Elsevier Inc. 581
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Microenvironmental Regulation of CML Stem Cellsendogenous human promoter, the patterns of BCR-ABL expres-
sion in murine cells are in general consistent with previous
reports for human CML subpopulations (Jamieson et al., 2004).
Cell cycle status of stem and progenitor populations was evalu-
ated by administration of 5-ethynyl-20-deoxyuridine (EdU). EdU
labeling of BM LTHSC was significantly reduced compared to
total LSK cells in both normal and CML mice (Figure S3C).
However, cycling of BCR-ABL+ LTHSC was increased
compared to control mice, both in vivo (Figure 4A) and in vitro
(data not shown). Ki-67 and 40, 6-diamidino-2-phenylindole
(DAPI) labeling showed a modest increase in the proportion of
BM LTHSC from BCR-ABL mice in S/G2/M phase compared to
control mice (Figure 4B). LTHSC from the spleen of BCR-ABL
mice showed significantly increased S/G2/M phase cells and
reduced G0 cells compared to splenic LTHSC from control
mice. These results demonstrate modest increase in cycling of
LTHSC in the BM and greater increase in cycling of LTHSC in
the spleen of BCR-ABL mice.
Reduced Homing and Retention of BCR-ABL Expressing
LTHSC in BM and Increased Egress to Spleen
We evaluated whether altered LTHSC localization, with reduced
BM LTHSC and increased splenic LTHSC, was related to
impaired LTHSC homing and/or reduced retention in BM. To
evaluate homing, CFSE-labeled LTHSC were injected intrave-
nously into irradiated recipients and CFSE-labeled cells in the
BM and spleen of recipient mice evaluated after 4 hr (Figure 4C).
There was reduced homing of BCR-ABL+ LTHSC to the BM of
recipient mice compared to controls (p = 0.04), with similar levels
of homing to spleen (Figure 4D). To study retention of LTHSC in
the BM, BCR-ABL+ and control LTHSC were injected directly
into the femur of irradiated congenic mice (Figure 4E). We
observed significantly increased numbers of BCR-ABL+ LTHSC
in the spleen and decreased numbers of BCR-ABL+ LTHSC in
the injected and contralateral femur of recipient mice at four
weeks postinjection (Figure S3D). In contrast, control LTHSC
were present in increased numbers in the BMand lower numbers
in the spleen of recipient mice, after both intrafemoral and
intravenous transplantation (Figure 4F). Increased egress of
BCR-ABL+ LTHSC was not related to increased BM cellularity
since total BM cell counts were not increased in CML mice
compared to normal mice (Figure 4G). These results indicate
that both reduced homing to the BM and enhanced egress
from the BM to the spleen contribute to altered LTHSC localiza-
tion in BCR-ABL mice.
Altered Chemokine and Cytokine Expression
in BCR-ABL Mice
The chemokine CXCL12 mediates hematopoietic cell localiza-
tion to the BM through interactions with the CXCR4 receptor
on hematopoietic cells (Peled et al., 1999). Enzyme-linked immu-
nosorbent assay (ELISA) analysis demonstrated significantly
reduced CXCL12 levels in the BM and a marginal increase of
CXCL12 levels in the spleen of BCR-ABL mice compared to
control mice (Figure 5A). We also observed reduced CXCL12
mRNA levels in BM cells from BCR-ABL mice compared to
controls (Figure 5B). CXCL12 mRNA was expressed at higher
levels in CD45Ter119 nonhematopoietic stromal cells com-
pared with CD45+ hematopoietic cells (Figure 5C). CXCL12582 Cancer Cell 21, 577–592, April 17, 2012 ª2012 Elsevier Inc.mRNA levels were significantly lower in BM stromal cells from
BCR-ABL mice compared to controls. Reduced CXCL12
expression may contribute to reduced retention of LTHSC in
the BM of BCR-ABL mice. In the spleen, CXCL12 was mainly
expressed in CD45Ter119-CD31 nonhematopoietic, nonen-
dothelial stromal cells, and levels were increased in CML
compared to control mice (Figure 5D).
We evaluated the levels of additional chemokines and cyto-
kines in BCR-ABL and control mice using Luminex xMAP
technology. In contrast to reduced CXCL12 levels, several
chemokines, including MIP-1a and MIP-1b, and cytokines,
including IL-1a, IL-1b, IL-6, G-CSF, TNF-a, and LIF, showed
increased expression in BM of BCR-ABL mice (Figures 5E and
S4A–S4M). Expression of mRNA for MIP-1a, MIP-1b, IL-1a,
IL-1b, IL-4, MIP-2, and IL-6 was significantly higher in both
hematopoietic cells and, to a lesser extent, nonhematopoietic
cells from the BM of BCR-ABL compared to control mice
(Figures S4N–S4T). Levels of several chemokines/cytokines
were also increased in the spleen of BCR-ABL mice compared
with control mice (Figures 5E and S4A–S4M). An additional
subset of chemokines and cytokines, including VEGF, IL-9,
and MIG, were selectively enhanced in the spleen but not BM
of BCR-ABL compared to control mice. These observations
indicate complex alterations of cytokine and chemokine pro-
duction by leukemic and stromal cells in the BM and splenic
microenvironment of BCR-ABL mice.
Coculture with BM cells and BM plasma from BCR-ABL mice
resulted in reduced CXCL12 mRNA levels in murine BM stromal
cells (M2-10B4), compared to BM cells (Figure 5F) and BM
plasma (Figure 5G) from control mice, indicating that reduced
CXCL12 expression is related to diffusible factors produced by
leukemia cells. Culture of stromal cells with MIP-1a, MIP-1b,
IL-1a, IL-1b, TNF-a, G-CSF, or IL6 (at concentrations similar to
those measured in BCR-ABL BM plasma) indicated that
CXCL12 mRNA levels are reduced in stromal cells cultured
with G-CSF and, to a lesser extent, MIP-1b and IL-6 (Figure 5H).
The addition of a function-blocking anti-G-CSF antibody
increased CXCL12 levels in stromal cells exposed to CML BM
plasma (Figure 5I). Finally, BCR-ABL mice treated with func-
tion-blocking anti-mouse G-CSF antibody or isotype control
antibody demonstrated enhanced CXCL12 levels in BM cells
and enhanced numbers of BM and reduced numbers of splenic
LTHSC (Figure 5J). These results support an important role for
G-CSF-mediated reduction in CXCL12 levels in altered LTHSC
localization in BCR-ABL mice.
Differential Regulation of Normal and Leukemic LTHSC
Growth by the CML BM Microenvironment
In view of the observed abnormalities of chemokine and cytokine
expression, we investigated whether BCR-ABL mice demon-
strated altered capacity to support LTHSC engraftment. LTHSC
from control or BCR-ABL mice were transplanted into irradiated
BCR-ABL mice (induced for four weeks) or control recipient
mice by tail vein injection (Figure 6A). BCR-ABL mice showed
mild to modest elevation in WBC count; most of them had not
developed leukemia and were not sick. Since it was not clear
how long leukemia-induced microenvironmental alterations
could be sustained after myeloablative treatment, mice were
followed for up to four weeks after transplantation. We observed
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Figure 4. Alterations in Cell Cycle, Homing, and Trafficking of BCR-ABL-Expressing LTHSC
(A) Percentage of cycling LTHSC in the BM of BCR-ABL and control mice evaluated 2 hr after in vivo administration of EdU. Representative flow cytometry plots
(left) and combined results (right) are shown (n = 3).
(B) The proportion of LTHSC from the BM and spleen of BCR-ABL and control mice in G0, G1, and S/G2/M phase evaluated by labeling with Ki-67 and DAPI.
Representative flow cytometry plots (left) and combined results (right) are shown (n = 3).
(C) CFSE-labeled LTHSC were transplanted by tail vein injection into irradiated congenic recipient mice and the number of CFSE-expressing cells in the BM and
spleen of recipient mice were evaluated 4 hr after injection.
(D) Homing of BCR-ABL and control LTHSC to the marrow and spleen of recipient mice after IV injection is shown (n = 8).
(E) GFP+ BCR-ABL or control LTHSC (1,000 cells/mouse) were injected directly into the right femur of irradiated congenic mice. Donor GFP+ LTHSC numbers in
the injected femur; contralateral femur and spleen were analyzed two weeks and four weeks after transplantation.
(F) Mice receiving control and BCR-ABL+ LTHSC administered intrafemorally or IV were analyzed after four weeks (n = 8 for both). The number of donor GFP+
LTHSC in the injected femur, contralateral femur, and the spleen were analyzed following intrafemoral transplantation, and the number of LTHSC per femur and in
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(G) The BM cellularity at four weeks after transplantation is shown. Results represent mean ± SEM. Significance values: *p < 0.05; ns, not significant, compared
with controls, or as indicated.
See also Figure S3.
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Figure 5. Altered Chemokine and Cytokine Expression in BCR-ABL Mice
(A–D) CXCL12 levels (A) measured by ELISA in peripheral blood and BM plasma and spleen supernatants from control and BCR-ABLmice. CXCL12mRNA levels
measured by qRT-PCR in (B) total BM cells; (C) BM hematopoietic cells (CD45+) and BM stromal cells (CD45Ter119); and (D) splenic B cells (CD45+B220+),
neutrophils (CD45+Gr-1+), endothelial cells (CD45-Ter119-CD31+), and nonendothelial stromal cells (CD45Ter119CD31) cells from control and BCR-ABL
mice.
(E–G) Expression of cytokines and chemokines (E) in peripheral blood and BM plasma and spleen supernatants from BCR-ABL-expressing and control mice
measured by ELISA using Luminex xMAP technology. CXCL12 mRNA levels in M2-10B4 murine stromal cells cocultured for 48 hr with (F) BM cells and (G) BM
plasma from BCR-ABL and control mice.
(H) CXCL12mRNA levels inM2-10B4murine stromal cells cultured for 24 hr in serum-freemediumwithout addition of cytokines or withMIP-1a (16 ng/ml), MIP-1b
(8 ng/ml), IL-1a (2.5 ng/ml), IL-1b (3.5 ng/ml), TNF-a (0.05 ng/ml), G-CSF (0.2 ng/ml), or IL-6 (2 ng/ml).
(I) CXCL12 mRNA levels in M2-10B4 murine stromal cells following culture for 24 hr with BM plasma from control and BCR-ABL mice, together with a function
blocking anti-mouse G-CSF antibody (50 and 100 ng/ml) or isotype control antibody.
(J) BCR-ABL mice were induced for one week and then were treated with function-blocking anti-mouse G-CSF antibody (10 mg/mouse, IV, once per day) or
isotype control antibody for an additional two weeks. CXCL12 mRNA levels in the BM and the numbers of LTHSC cells in the BM and spleen were measured.
Results represent mean ± SEM. Significance values: *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
See also Figure S4.
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Figure 6. Differential Regulation of Normal and Leukemic LTHSC Growth by the CML BM Microenvironment
(A) GFP+ LTHSC (1,000 cells/mouse) from control or BCR-ABL mice were transplanted into irradiated BCR-ABL or control mice by tail vein injection (n = 16 for
each group, with a total of 64 mice at two weeks and 64 mice at four weeks).
(B) The numbers of GFP+ LTHSC in the BM and spleen of irradiated control and BCR-ABL recipient mice at two weeks posttransplant.
(C) Homing of CFSE-labeled control LTHSC transplanted by tail vein injection into irradiated control and BCR-ABL recipient mice evaluated 4 hr after injection
(n = 8).
(D) The numbers of GFP+ LTHSC in the BM and spleen of irradiated control and BCR-ABL recipient mice at four weeks posttransplant.
(E) Control LTHSC and BCR-ABL+ LTHSC were cultured with BM plasma obtained from control and BCR-ABLmice. Results shown represent fold-change in cell
numbers after two days of culture (n = 3).
(F–H) BCR-ABL+ LTHSC (CD45.1) and control LTHSC (CD45.2) (F) were mixed in a 1:1 ratio and cultured with CML or control BM conditioned medium (CM). The
proportion of input cells was checked using flow cytometry. The ratio of CD45.1:CD45.2 cells at different times is shown (n = 3). CFSE+ LTHSC from control and
BCR-ABL-expressing mice were cultured with serum-free mediumwithout cytokine or supplemented with MIP-1a (16 ng/ml), MIP-1b (8 ng/ml), IL-1a (2.5 ng/ml),
IL-1b (3.5 ng/ml), TNF-a (0.05 ng/ml), G-CSF (0.2 ng/ml), or IL-6 (2 ng/ml) for 72 hr and cell growth (G) and proliferation (H) were measured. Results represent
mean ± SEM. Significance values: *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
See also Figure S5.
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Microenvironmental Regulation of CML Stem Cellsreduced engraftment of both control and BCR-ABL+ LTHSC in
the BM of BCR-ABL recipients compared with control recipients
two weeks after transplantation (Figure 6B), associated with
reduced homing of control LTHSC (Figure 6C) and BCR-ABL+
LTHSC (Figure 4D) to the BM of BCR-ABL compared to control
mice, possibly related to low BM CXCL12 levels (Figures 5A
and 5B). The numbers of control LTHSC in the BM of BCR-
ABL recipient mice remained low, whereas BCR-ABL+ LTHSC
were increased four weeks after transplant and were similar to
the numbers seen in the BM of control recipients (Figure 6D).
Similar results were seen for CD48+MPP, committed progeni-
tors, and total GFP+ leukemic cells (Figures S5A and S5C). There
was no difference in the number of engrafted LTHSC or progen-
itor cells in the spleen of BCR-ABL and control mice at two
weeks (Figures 6B and S5B), but there was a modest increase
in LTHSC but not progenitor engraftment in the spleen of BCR-
ABL mice at four weeks after transplantation (Figures 6D and
S5D). These results suggest that increased splenic CXCL12
expression may not be sufficient to increase LTHSC homing
but may contribute to increased relocalization of LTHSC to the
spleen at later times. Lack of increased homing of normal LTHSC
to CML spleen despite increased CXCL12 levels may reflect
the involvement of additional factors besides CXCL12 in the
homing process.
In vitro exposure to BM plasma from CML mice resulted in
impaired growth of control LTHSC compared to BM plasma
from control mice. In contrast, growth of BCR-ABL+ LTHSC
was similar after exposure to CML and control BM plasma (Fig-
ure 6E), suggesting that diffusible factors produced by leukemia
cells contribute to reduced growth of normal compared to BCR-
ABL+ LTHSC in the BM microenvironment of BCR-ABL mice,
resulting in a growth advantage for the leukemic clone. To
directly test the hypothesis, we performed a competitive in vitro
assay in which BCR-ABL+ LTHSC (CD45.1) and control LTHSC
(CD45.2) were mixed in a 1:1 ratio and cultured with CML or
control BM-conditioned medium (CM). The proportion of the
input cells was checked every three days using flow cytometry.
We observed a markedly enhanced proportion of BCR-ABL+
compared with control cells following culture with CML CM,
whereas the proportion of BCR-ABL+ and control cells was
similar following culture with control CM (Figure 6F). These
results indicate that factors produced by CML BM cells confer
a competitive growth advantage to BCR-ABL+ LTHSC over
control LTHSC. We further show that the growth of control
LTHSC was reduced compared to BCR-ABL+ LTHSC in the
presence of MIP-1a, MIP-1b, IL-1a, IL-1b, and TNF-a (at
concentrations similar to those in BM plasma from BCR-ABL
mice; Figure 6G). Reduced growth was related to reduced prolif-
eration of control compared to BCR-ABL+ LTHSC (Figure 6H),
without significant changes in apoptosis (Figure S5E).
We examined the effect of IM treatment on BM microenviron-
mental function in BCR-ABL mice. LTHSC from control mice
were transplanted into irradiated control or BCR-ABL mice that
had been treated or not treatedwith IM for twoweeks (Figure 7A).
LTHSC engraftment was increased in IM-treated BCR-ABL
mice, indicating at least partial correction of the microenviron-
mental defect (Figure 7B). We observed increased expression
of CXCL12 and reduced expression of G-CSF, IL-6, IL-1b,
MIP-1a, and MIP-1b in BM cells from IM-treated compared to586 Cancer Cell 21, 577–592, April 17, 2012 ª2012 Elsevier Inc.untreated BCR-ABL mice (Figure 7C). Levels of IL-1a, IL-4, and
MIP-2 were not significantly changed. Enhanced growth of
normal LTHSC in the BM of BCR-ABL mice pretreated with IM
was associated with enhanced CXCL12 and reduced cytokine
levels.
Cytokine and Chemokine Expression in Human
CML BM Cells
We analyzed cytokine and chemokine expression in BM cells
from newly diagnosed CML CP patients, CML CP patients in
complete cytogenetic remission (CCR) on IM treatment, and
from healthy controls. CML BM cells demonstrated reduced
expression of CXCL12 and increased expression of G-CSF,
IL-1a, MIP-1b, and MIP-2, compared to normal BM cells. BM
cells from patients in CCR showed increased CXCL12 and
reduced G-CSF, TNF-a, and MIP-2 expression without signifi-
cant change in other factors (Figures 8A and S6A). However,
CXCL12 levels in CML patients in CCR remained significantly
lower than in normal BM. Immunohistochemical analysis of
BM sections from newly diagnosed CML CP patients showed
reduced CXCL12 labeling compared to untreated lymphoma
patients without BM involvement as controls. BM sections
from the same CML patients after six months or more of IM
treatment showed increased CXCL12 staining (Figures 8B and
S6B). CXCL12 expression was seen in stromal cells and in
a subset of mature hematopoietic cells. In contrast, G-CSF
expression was increased in hematopoietic cells in BM sections
from CML patients compared to controls and was reduced after
IM treatment (Figures 8C and S6B). Primary human stromal cells
immortalized with hTERT (Mihara et al., 2003) were exposed to
conditioned medium (CM) made with BM cells from control
and CML CP patients. Exposure to CML CM resulted in reduced
CXCL12 in stromal cells compared to control CM (Figure 8D).
CXCL12 expression was partially restored by the addition of an
anti-G-CSF blocking antibody. These results support a role for
increased G-CSF expression by CML hematopoietic cells in
reduced CXCL12 production by human stromal cells, validating
the results obtained with the murine model.
Primitive CD34+CD38 cells from newly diagnosed CML CP
patients and control healthy individuals were cultured with CP
CML and normal BM CM. Culture with CML CM reduced growth
of normal but not CML CD34+CD38 cells in luminescent cell
viability (Figure 8E) and CFC assays (Figure 8F). Human CML
and normal CD34+CD38 cells were also cultured without
cytokines or with MIP-1b, MIP-2, IL-1a, and G-CSF—the four
cytokines significantly increased in the BM cells from CML CP
patients. IL-1a and G-CSF treatment resulted in significantly
less expansion of normal compared to CML CD34+CD38 cells,
compared to controls cultured without cytokines in luminescent
cell viability (Figure 8G) and CFC assays (Figure 8H), related to
reduced proliferation of normal compared to CML CD34+CD38
cells (Figure S6C), consistent with results obtained with the
mouse model.
DISCUSSION
The transgenic BCR-ABL mouse demonstrates gradual devel-
opment of a myeloproliferative disorder with neutrophilic leuko-
cytosis, extramedullary hematopoiesis, and splenomegaly and
     Engraftment of Control LTHSC
C
trl
B
/A
B
/A
+I
M
0
500
1000
1500
2000
2500 p=0.06
*
*
c
e
ll 
n
u
m
b
e
r
900 cGy
Control 
GFP
+
Control LTHSC
BCR-ABL
900 cGy
• Cytokine  
levels
• Engraftment
900 cGy
BCR-ABL
Induce  4 weeks
Induce  4 weeks
IM x 2 weeks
2 weeks
A
B
C
CXCL12
B
/A
B
/A
+I
M
0.000
0.001
0.002
0.003
0.004
***
C
X
C
L
1
2
/G
A
P
D
H
G-CSF
B
/A
B
/A
+I
M
0.000000
0.000002
0.000004
0.000006
0.000008
0.000010 *
G
-C
S
F
/G
A
P
D
H
IL-4
B
/A
B
/A
+I
M
0.00000
0.00002
0.00004
0.00006
0.00008
0.00010
ns
IL
-4
/G
A
P
D
H
MIP-2
B
/A
B
/A
+I
M
0.0000
0.0001
0.0002
0.0003
0.0004 ns
M
IP
-2
/G
A
P
D
H
IL-6
B
/A
B
/A
+I
M
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
***
IL
-6
/G
A
P
D
H
IL-1α
B
/A
B
/A
+I
M
0.000
0.005
0.010
0.015
0.020 ns
IL
-1
α
/G
A
P
D
H
IL-1β
B
/A
B
/A
+I
M
0.0000
0.0005
0.0010
0.0015 p=0.05
IL
-1
β/
G
A
P
D
H
MIP-1β
B
/A
B
/A
+I
M
0.0000
0.0005
0.0010
0.0015
0.0020
***
M
IP
-1
β/
G
A
P
D
H
MIP-1α
B
/A
B
/A
+I
M
0.000
0.002
0.004
0.006
0.008 ***
M
IP
-1
α
/G
A
P
D
H
Figure 7. Effect of IM Treatment on Cytokine Levels on CML BM Microenvironmental Function
(A) One thousand GFP+ control LTHSC/mouse were sorted and transplanted into irradiated control mice, BCR-ABL mice (induced four weeks), and BCR-ABL
mice treated with IM for the last two weeks of the induction period (n = 8 each).
(B) Engraftment of control LTHSC in the BM of irradiated control, BCR-ABL, and IM-treated BCR-ABL mice.
(C) Cytokine and chemokine mRNA levels in the BM of BCR-ABL mice treated with or without IM were measured. Results represent mean ± SEM. Significance
values: *p < 0.05; **p < 0.01, n = 8.
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Microenvironmental Regulation of CML Stem Cellsprovides a representativemodel of human CPCML.We used the
transgenic BCR-ABL mouse model to identify LSC with a high
degree of resolution and to characterize their microenviron-mental regulation. Long-term engraftment and leukemia-
initiating capacity was restricted to a small subfraction of LSK
cells that had the LTHSC (Flt3CD150+CD48) phenotype.Cancer Cell 21, 577–592, April 17, 2012 ª2012 Elsevier Inc. 587
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Figure 8. Cytokine and Chemokine Expression in Human CML BM Cells
(A) Cytokine and chemokine mRNA levels in BM MNC from control, newly diagnosed CML CP patients and CML CP patients in complete cytogenetic remission
(CCR) on IM treatment were measured by qRT-PCR and results were normalized to actin expression.
(B and C) CXCL12 (B) and G-CSF (C) expression in BM sections obtained from untreated lymphoma patients without BM involvement by disease (NL), newly
diagnosed CML CP patients prior to starting IM treatment (pre-IM), and the same patients after six months or more of IM treatment (post-IM) were analyzed by
immunohistochemistry (n = 3). Scale bars represent a size of 10 mm.
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Cancer Cell
Microenvironmental Regulation of CML Stem CellsIn contrast, LSK cells with MPP or LMPP phenotypes generated
only short-term engraftment. These results indicate that CML
originates from transformation at the level of the LTHSC rather
than more differentiated MPP or LMPP and that leukemic hema-
topoiesis follows a hierarchical differentiation pattern as seen in
normal hematopoiesis. These results are consistent with a recent
report in which SCL-tTA/BCR-ABL mice in the C57BL/6 back-
ground were studied (Reynaud et al., 2011). In contrast to the
FVB/N strain, leukemia developing in C57BL/6 background
mice is more aggressive with a higher incidence of BM fibrosis
and hypocellularity, and secondary lymphoid disorders are not
seen, suggesting that strain-specific factors modulate the
phenotype and course of leukemia. Our results contrast with
observations made in BC CML and acute myeloid leukemia,
where more mature LMPP or GMP progenitors may acquire
self-renewal and leukemia-initiating capacity (Jamieson et al.,
2004; Sarry et al., 2011).
LTHSC numbers were reduced in the BM of CML mice, with
a concomitant increase in MPP, suggesting enhanced LTHSC
differentiation and enhanced proliferation and expansion
of MPP. CML MPP generated short-term engraftment with
predominantly myeloid cells after transplantation, whereas
CML LMPP generated expanded populations of immature pro-
B cells after transplantation. Although CML LTHSC can generate
progeny with both myeloid and lymphoid potential, selective
expansion of the myeloid population is seen following the trans-
plantation of purified LTHSC and lymphoid cells are suppressed.
The recent report that IL-6 produced by leukemic cells inhibits
lymphoid and promotes myeloid differentiation and expansion
of the leukemic clone could provide an explanation for these
findings (Reynaud et al., 2011).
We observed reduced BM and increased splenic LTHSC in
BCR-ABL mice related to decreased LTHSC homing to the
BM, reduced retention in the BM and increased egress to the
spleen, and enhanced proliferation in the spleen. The abnormal
trafficking and growth of BCR-ABL+ LTHSC indicates alterations
in microenvironmental interactions compared to normal
LTHSC. Intrinsic defects in adhesion receptors, including b1 in-
tegrins (Verfaillie et al., 1992) and CD44 (Krause et al., 2006),
may be seen in CML progenitor cells. In addition, migration of
CML progenitors to CXCL12 is reported to be reduced
compared to normal progenitors (Jin et al., 2008; Peled et al.,
2002). We identified reduction in BMCXCL12 levels as a mecha-
nism underlying impaired LTHSC homing and retention in CML
BM. CXCL12 expression in BM stromal cells was reduced in
both BCR-ABLmice and CML patients. Since CXCL12 regulates
LTHSC quiescence, reduced CXCL12 levels could directly
contribute to increased cycling of LTHSC in the BM of BCR-
ABL mice (Cashman et al., 2002). In addition, reduced CXCL12(D) Primary human stromal cells immortalized with hTERT expression were expos
24 hr. The effect of addition of a blocking anti-human G-CSF (10 mg/ml) antibody
(E–H) CD34+CD38 cells (E) from control and newly diagnosed CML CP patients
newly diagnosed CML CP patients and cell growth measured using a luminescen
diagnosed CML CP patients were labeled with CFSE. CFSE+ LinCD34+CD38
cytokines or supplemented with MIP-1b (10 and 50 ng/ml), MIP-2 (1 and 10 ng/m
MIP-1b, 1 ng/ml MIP2, 1 ng/ml IL-1a, and 50 ng/ml G-CSF). Cell growth was m
represent mean ± SEM. Significance values: *p < 0.05; **p < 0.01; ***p < 0.001; n
See also Figure S6.expression could contribute to abnormal regulation of LTHSC
proliferation and differentiation indirectly by altering their niche
localization.
Growth of normal LTHSC was reduced in the BM of BCR-ABL
mice compared to control mice, whereas BCR-ABL+ LTHSC
demonstrated similar growth in the BM of BCR-ABL and normal
mice, related to diffusible factors produced by CML BM cells.
These results are consistent with our previous observations
that normal human progenitors demonstrate impaired in vitro
growth on stromal layers derived from human CML BM but
that growth of human CML progenitors is similar on normal
and CML BM-derived stromal layers (Bhatia et al., 1995) and
suggest that altered BM microenvironmental function contrib-
utes to suppression of normal LTHSC and provides a selective
advantage to LSC in CML. Expression of several other chemo-
kines and cytokines was significantly increased in the BM
of BCR-ABL mice. These cytokines were produced mainly by
leukemic hematopoietic cells. We identified the chemokines
MIP-1a and b and the cytokines IL-1a and b and TNF-a as sup-
porting reduced proliferation and growth of normal compared to
CML LTHSC. Relevant to these findings it has been previously
reported that certain chemokines selectively inhibit the prolifera-
tion of normal progenitors while sparing CML progenitors (Cash-
man et al., 1998; Eaves et al., 1993) and that CML LTHSC have
enhanced expression of proteins affecting IL-1 signaling (Ja¨ra˚s
et al., 2010). Additional as yet unidentified inhibitory factors
could also contribute to selective inhibition of normal LTHSC
in the CML BM microenvironment. Growth of normal LTHSC
was enhanced in the BM micro-environment of IM-treated,
compared to untreated BCR-ABL, mice in association with
reduced levels of several of the abnormally expressed cytokines.
These results support a role for specific cytokines produced by
leukemic cells within the CML BM microenvironment in confer-
ring a growth advantage to CML compared with normal LTHSC.
Cytokine alterations, in addition to direct effects on LTHSC,
may also indirectly affect LTHSC by altering the function of
stromal cells (Bonig et al., 2006). The cytokines G-CSF, IL-1,
and TNF-a can suppress expression of CXCL12 in osteoblasts
or fibroblastic cells (Peng et al., 2006; Zhang et al., 2008). We
identified an important role for G-CSF produced by leukemic
cells in reducing CXCL12 expression in CML BM stromal cells.
Inhibition of G-CSF activity increased CXCL12 levels in BM
stromal cells in vitro and in vivo, leading to increased retention
of LTHSC in the BM and reduced LTHSC in the spleen of
BCR-ABL mice. CXCL12 expression was increased and
G-CSF expression was reduced in the BM of IM-treated BCR-
ABL mice and in the BM of CML patients in remission following
IM treatment. Restoration of normal niche interactions could
play a role in leukemia control in a physiological setting.ed to CM made with BM MNC from healthy controls and CML CP patients for
or isotype control antibody on CXCL12 mRNA levels was evaluated.
were cultured for 48 hr with CM made with BMMNC from healthy controls and
t cell viability assay and (F) in CFC assays. CD34+ cells from normal and newly
cells were sorted and cultured for 72 hr in serum-free medium either without
l), IL-1a (1 and 10 ng/ml), G-CSF (10 and 50 ng/ml), or a combination (10 ng/ml
easured using a (G) luminescent viability assay and (H) in CFC assay. Results
s, not significant.
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Microenvironmental Regulation of CML Stem CellsHowever, CXCL12 levels in CMLBMafter IM treatment remained
lower than in normal BM, indicating that recovery of CXCL12
expression is incomplete. Although our studies demonstrate
reduced CXCL12 mRNA expression by stromal cells in CML,
we recognize that additional mechanisms, such as increased
CXCL12 cleavage by proteolytic enzymes, could also be active
(Cho et al., 2010).
These studies support important, new concepts regarding
the contribution of leukemia-induced alterations in the BM
microenvironment to a selective growth advantage to leukemic
compared with normal LTHSC and have relevance to our under-
standing of the response and resistance to TKI at the organismal
level. Although IM treatment corrects several abnormalities in
cytokine and chemokine expression in CML cells and reduces
normal LTHSC inhibition by leukemic cells and facilitates their
regrowth, it does not completely reverse leukemia-associated
changes in the microenvironment. It will be important to deter-
mine the mechanisms underlying these persistent changes and
how leukemia-related alterations in the hematopoietic micro-
environment affect LSC response to TKI treatment, regrowth of
normal LTHSC, and persistence of LSC in CML patients on pro-
longed TKI treatment. These insights could lead to improved
strategies to eliminate resistant LSC populations in TKI-treated
patients.
EXPERIMENTAL PROCEDURES
Mice
Inducible, transgenic SCL-tTa/BCR-ABL mice in the FVB/N background
(Koschmieder et al., 2005) were maintained with administration of tetracycline
in the drinking water (0.5 g/l) and were crossed with transgenic GFP-express-
ing mice (FVB.Cg-Tg [ACTB-EGFP] B5Nagy/J; Jackson Laboratories, Bar
Harbor, ME) for transplantation experiments to facilitate tracking of donor
cells. If not indicated, BCR-ABL expression was induced for three weeks by
tetracycline withdrawal. Mouse care and experimental procedures were per-
formed in accordance with federal guidelines and protocols approved by the
Institutional Animal Care and Use Committee at the City of Hope.
Samples
Aliquots of normal peripheral blood and BM mononuclear cells (MNC) were
obtained from allogeneic transplant donors. CML samples were obtained
from patients in CP who had not received prior IM treatment from City of
Hope and the University of Glasgow. Sample acquisition was approved by
the Institutional Review Boards (IRB) at City of Hope, and the North Glasgow
University Hospital Division of NHS Greater Glasgow and Clyde in accordance
with the Declaration of Helsinki. All donors signed informed consent forms. BM
sections from NHL patients were obtained from the City of Hope Biospecimen
Repository, as anonymized specimens, using an IRB-approved protocol
which exempted consent requirements. MNC were isolated using Ficol sepa-
ration. CD34+ cells were isolated using a positive magnetic bead selection
protocol (Miltenyi, Auburn, CA, USA).
Flow Cytometry
Cells were obtained from BM (both tibias and femurs), lymph nodes, or spleen.
All analyses were performed on an LSRII flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). Myeloid progenitors were identified as LinSca-
1c-Kit+CD34+FcgRII/IIIlo (CMP), LinSca-1c-Kit+CD34+FcgRII/IIIhi (GMP),
or LinSca-1c-Kit+CD34FcgRII/IIIlo (MEP; Akashi et al., 2000). Stem and
multipotent progenitor populations were identified as LSK cells (LinSca-
1hic-Kithi), LTHSC (LSK Flt3CD150+CD48), MPP (LSK Flt3CD150CD48-,
LSK Flt3CD150+CD48+, LSK Flt3CD150CD48+) and LMPP (LSK Flt3+
CD150; Kiel et al., 2005). Human stem cells/primitive progenitors were iso-
lated by sorting CD34+CD38 cells. For cell cycle analysis EdU (Invitrogen,
Grand Island, NY, USA) was administered intraperitoneally (1 mg/mouse),590 Cancer Cell 21, 577–592, April 17, 2012 ª2012 Elsevier Inc.BM cells were obtained 2 hr postinjection and EdU incorporation into stem
cell populations analyzed (Cappella et al., 2008). Cell cycle was also analyzed
by Ki-67 (BD) and DAPI labeling as previously described (Jordan et al., 1996).
Details are provided in the Supplemental Experimental Procedures.
Transplantation
GFP+ BM cells or purified progenitor populations from BCR-ABL/GFP
transgenic mice and control mice were injected into 8-week-old FVB/N or
BCR-ABL mice irradiated at 900 cGy. To evaluate homing, LTHSC were
labeled with 1.25 mMCFSE (Molecular Probes, Eugene, OR, USA) and injected
intravenously, and the percentage of CFSE+ cells in the BM and spleen was
analyzed after 4 hr. To evaluate egress of cells from the BM to the spleen,
GFP+ LTHSC cells were injected into the right femur of FVB/N mice irradiated
at 900 cGy, and the number of GFP+ LTHSC in the right femur, left femur, and
spleen of mice was analyzed after two and four weeks. For some experiments,
mice were treated with IM for two weeks pretransplantation. Details are
provided in the Supplemental Experimental Procedures.
Measurement of Cytokine Levels
BM, peripheral blood, and spleen cell suspensions were centrifuged and
supernatants were aliquoted and frozen. ELISA assays for CXCL12 (R&D
Systems, Minneapolis, MN, USA; MCX120) and Luminex xMAP assays for
a panel of murine cytokines and chemokines (MILLIPLEX MAP Mouse Cyto-
kine/Chemokine Panel from Millipore, Billerica, MA, USA; MPXMCYTO-70K)
were performed. Expression of mRNA for different cytokines and chemokines
in human and murine BM and spleen cells were analyzed using quantitative
reverse transcriptase-polymerase chain reaction (qRT-PCR). CXCL12 and
G-CSF expression in BM sections from CML patients and controls were
analyzed by immunohistochemistry. Details are provided in the Supplemental
Experimental Procedures.
Statistics
Results are expressed as means ± standard error of means. Significance was
estimated using Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at doi:10.1016/j.ccr.2012.
02.018.
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